Chugai Pharmaceutical Co Ltd (4519) Stock Price & News

4519:TYO

Chugai Pharmaceutical Co Ltd

¥6,653.00

+0.59%

(+39.00) 1D

Oct 29, 3:30:00 PM GMT+9 · JPY

All symbols

	Symbol	Price	Change	% Change

Last report

Oct 27, 2026

Fiscal period

Q3 2026

- / -

Revenue / Est. (JPY)

404.70B / 349.46B

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in JPY

Loading Previous Earnings...

All values in JPY	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	333.18B	346.30B	321.75B	341.58B
Cost of goods sold	100.24B	87.56B	92.79B	104.22B
Cost of revenue	100.24B	87.56B	92.79B	104.22B
Research and development expenses	48.60B	52.41B	41.89B	47.76B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	27.89B	36.92B	28.90B	29.04B
Operating expense	76.45B	89.74B	70.19B	76.51B
Total operating expenses	176.69B	177.30B	162.98B	180.73B
Operating income	156.48B	169.01B	158.76B	160.86B
Other non operating income	-356.00M	994.00M	1.43B	3.04B
EBT including unusual items	156.07B	169.90B	160.20B	169.02B
EBT excluding unusual items	156.07B	169.90B	160.20B	169.02B
Income tax expense	44.86B	41.50B	44.78B	52.69B
Effective tax rate	28.74%	24.42%	27.95%	31.17%
Other operating expenses	-38.00M	405.00M	-596.00M	-291.00M
Net income	111.21B	128.41B	115.42B	116.33B
Net profit margin	33.38%	37.08%	35.87%	34.06%
Earnings per share	-	-	-	-
Interest and investment income	-	-	-	5.13B
Interest expense	-58.00M	-95.00M	-	-
Net interest expenses	-58.00M	-95.00M	-	5.13B
Depreciation and amortization charges	-	-	-	-
EBITDA	156.78B	200.44B	159.26B	161.56B
Gain or loss from assets sale	-	4.53B	-	-

Finance